LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
Market Cap
$397.87M
MomentumView details →
1D Return
+0.00%
YTD Return
+0.66%
RSI (14)
43.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
Market Cap
$397.87M
RSI (14)
43.5
MomentumView details →
1D Return
+0.00%
YTD Return
+0.66%
SummaryUpdated Jun 1, 2026
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company founded in 2014 and based in Bala Cynwyd, Pennsylvania. The company specializes in developing innovative treatments for rare diseases using its proprietary cell penetrating peptide technology platform. Since going public in 2014, Larimar has focused its efforts on advancing novel therapeutic approaches for conditions that currently have limited or no treatment options, with its lead program targeting Friedreich's ataxia, a devastating genetic disorder.
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP increased its stake in Larimar Therapeutics, Inc. by 143.8% during the first quarter, purchasing an additional 470,968 shares, according to a recent SEC filing.23d agoLarimar Therapeutics reported a net loss of $32.8 million for Q2 2026, with a diluted loss per share of $0.30, compared to a net loss of $26.2 million in Q2 2025.32d ago